Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Arsenal Bridge Ventures is a venture capital firm founded in 2023 and based in Austin, Texas. The firm was established by Isaac Barchas, Jim Graham, and Jim Weiss, who collectively bring extensive experience in biotechnology business building and investing. Arsenal Bridge Ventures aims to advance biotechnology innovations, particularly from mid-continent research universities where commercial and venture networks are less developed.
The firm has evolved from its predecessor, Research Bridge Partners, which was co-founded by Isaac Barchas and Reid Hoffman. Arsenal Bridge Ventures currently manages multiple funds, including Arsenal Bridge Ventures II, II-B, III, and IV. The firm focuses on sourcing deals from underrepresented markets, emphasizing high-impact biotechnology innovations.
As of now, Arsenal Bridge Ventures has a portfolio of seven companies and employs a team of experienced professionals dedicated to building companies through strategic leadership recruitment and capital deployment. Their unique geographic strategy allows them to tap into opportunities that are often overlooked by traditional biotech hubs.
Arsenal Bridge Ventures invests primarily in biotechnology innovations, with a strong emphasis on opportunities arising from mid-continent research universities. The firm targets less crowded markets compared to traditional biotech hubs like Boston and San Francisco, allowing them to identify unique investment opportunities. Their investment strategy includes leadership recruitment, capital deployment, and syndication to optimize asset value.
The firm typically invests in companies at the Seed, Series A, and Series B stages, with check sizes starting at $7.8 million. Arsenal Bridge Ventures is particularly interested in high-impact deals within the biotech and healthcare sectors. Their thesis revolves around leveraging less saturated markets to source innovative biotechnology solutions, integrating AI and new technologies into their investment approach.
Arsenal Bridge Ventures has a diverse portfolio that includes seven notable companies:
Among these, MorphImmune and Novosteo are publicly traded, showcasing the firm's ability to identify and support companies that achieve significant market validation.
Isaac Barchas — Founding Partner. Co-founded Research Bridge Partners with Reid Hoffman and previously led the Austin Technology Incubator (ATI). He has extensive experience in biotechnology business building and investing.
Jim Graham — Founding Partner. Former Director of Investments at Research Bridge Partners' Catalyst Fund, bringing a wealth of knowledge in investment strategies within the biotech sector.
Jim Weiss — Partner. Founder of Real Chemistry and previously worked at Genentech and Rhone-Poulenc Rorer, contributing significant expertise in biotech operations and investments.
Reid Hoffman — Special Partner. Co-founder of LinkedIn and PayPal, he co-founded Research Bridge Partners and is actively involved in deal vetting and value creation.
Clay B. Siegall, PhD — Special Partner. Former CEO of Seagen, which was acquired by Pfizer for $43 billion in 2023. Currently CEO of Immunome, he brings deep industry insights and connections to the firm.
To pitch Arsenal Bridge Ventures, founders should use the preferred channel of their website at arsenalbridge.com or email info@arsenalbridge.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. The firm appreciates detailed information about the technology and its potential impact.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, especially from trusted industry contacts or existing portfolio founders.
In 2023, Arsenal Bridge Ventures was founded, marking a significant entry into the venture capital landscape focused on biotechnology. The firm has been actively building its portfolio, which currently includes seven companies, such as Tetricus and Eradivir.
Notably, MorphImmune and Novosteo are publicly traded, validating the firm's investment thesis. The firm emphasizes its unique geographic strategy, sourcing deals from mid-continent research universities.
In May 2025, Arsenal Bridge Ventures made a $7.8 million seed investment in Courage Therapeutics, a University of Michigan spinout focused on obesity and eating disorders.
What are Arsenal Bridge Ventures' investment criteria?
The firm focuses on high-impact biotechnology innovations, particularly those sourced from mid-continent research universities. They invest in companies at the Seed, Series A, and Series B stages, with check sizes starting at $7.8 million.
How can founders apply or pitch to Arsenal Bridge Ventures?
Founders can pitch their ideas through the firm's website at arsenalbridge.com or via email at info@arsenalbridge.com. It is recommended to include a detailed business plan and information about the team and technology.
What makes Arsenal Bridge Ventures different from other VC firms?
Arsenal Bridge Ventures differentiates itself by focusing on biotechnology innovations from mid-continent research universities, targeting less saturated markets compared to traditional biotech hubs. Their strategy includes leadership recruitment and capital deployment to enhance asset value.
What is the geographic scope of Arsenal Bridge Ventures?
The firm primarily invests in the United States, specifically targeting mid-continent regions where commercial and venture networks are less developed.
What is Arsenal Bridge Ventures' post-investment involvement like?
The firm actively engages with its portfolio companies through strategic leadership recruitment and leveraging the extensive networks of its partners, including industry leaders like Reid Hoffman and Clay B. Siegall.
What is the fund size and check size range for Arsenal Bridge Ventures?
Arsenal Bridge Ventures has multiple funds under management, with check sizes starting at $7.8 million. The firm focuses on building a portfolio of high-impact biotechnology companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.